DEA must ‘make good’ on marijuana rescheduling, Democratic lawmakers say
The U.S. Drug Enforcement Administration has offered federal lawmakers a rare glimpse into the ongoing marijuana rescheduling process.
The U.S. Drug Enforcement Administration has offered federal lawmakers a rare glimpse into the ongoing marijuana rescheduling process.
The U.S. Drug Enforcement Administration will sign off on moving marijuana to Schedule 3 of the Controlled Substances Act, one federal lawmaker believes.
Moving marijuana to Schedule 3 of the Controlled Substances Act, as Biden administration health officials have recommended, violates U.S. promises to other countries.
Oregon Democratic congressman Earl Blumenauer continues to push the U.S. Drug Enforcement Administration to reschedule marijuana and lay out a timeline for such action.
State-regulated medical cannabis programs and illicit users are at least in part to thank for the Biden administration’s recommendation that marijuana be moved from Schedule 1 to Schedule 3 of the Controlled Substances Act.
Attorneys general from 12 states sent a letter to the head of the U.S. Drug Enforcement Administration to “encourage” the DEA to reschedule marijuana.
Six Democratic governors have formally asked the Biden administration to move on rescheduling marijuana before the end of the calendar year.
The U.S. Drug Enforcement Administration will “likely” reschedule marijuana, following federal health regulators’ Aug. 29 recommendation, according to a government analysis.
Fourteen Republican federal lawmakers are voicing their opposition to a key federal agency’s recent recommendation that marijuana be rescheduled.
The most significant shift in U.S. marijuana policy is drawing closer, but one major obstacle remains in reform’s way: the Drug Enforcement Administration.
The disclosure Wednesday that top Biden administration health officials this week officially recommended marijuana be reclassified from a Schedule 1 substance to Schedule 3 – the same category as Tylenol with codeine – was hailed as the biggest development in MJ policy reform in more than 50 years.
The Biden administration has yet to provide the U.S. Drug Enforcement Administration a “specific timeline” to complete its review of marijuana’s status under federal law, the agency’s chief told members of Congress on Thursday.